CA2332963C - Combination meningitidis b/c vaccines - Google Patents

Combination meningitidis b/c vaccines Download PDF

Info

Publication number
CA2332963C
CA2332963C CA2332963A CA2332963A CA2332963C CA 2332963 C CA2332963 C CA 2332963C CA 2332963 A CA2332963 A CA 2332963A CA 2332963 A CA2332963 A CA 2332963A CA 2332963 C CA2332963 C CA 2332963C
Authority
CA
Canada
Prior art keywords
antigen
nmb
nmc
meningitidis
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2332963A
Other languages
English (en)
French (fr)
Other versions
CA2332963A1 (en
Inventor
Dan M. Granoff
Ingeborg S. Aaberge
Bjorn Haneberg
Johan Holst
Howard Raff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Statens Institutt for Folkehelse
Original Assignee
Statens Institutt for Folkehelse
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Institutt for Folkehelse, Novartis Vaccines and Diagnostics Inc filed Critical Statens Institutt for Folkehelse
Publication of CA2332963A1 publication Critical patent/CA2332963A1/en
Application granted granted Critical
Publication of CA2332963C publication Critical patent/CA2332963C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Beans For Foods Or Fodder (AREA)
CA2332963A 1998-05-29 1999-05-28 Combination meningitidis b/c vaccines Expired - Fee Related CA2332963C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8735198P 1998-05-29 1998-05-29
US60/087,351 1998-05-29
US10644698P 1998-10-30 1998-10-30
US60/106,446 1998-10-30
PCT/US1999/011977 WO1999061053A1 (en) 1998-05-29 1999-05-28 Combination meningitidis b/c vaccines

Publications (2)

Publication Number Publication Date
CA2332963A1 CA2332963A1 (en) 1999-12-02
CA2332963C true CA2332963C (en) 2013-07-23

Family

ID=26776879

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2332963A Expired - Fee Related CA2332963C (en) 1998-05-29 1999-05-28 Combination meningitidis b/c vaccines

Country Status (15)

Country Link
US (1) US8007815B1 (de)
EP (2) EP1079857B1 (de)
JP (2) JP5074644B2 (de)
AT (1) ATE346609T1 (de)
AU (2) AU761495B2 (de)
BR (1) BR9910749A (de)
CA (1) CA2332963C (de)
CY (1) CY1107550T1 (de)
DE (1) DE69934225T2 (de)
DK (1) DK1079857T3 (de)
ES (2) ES2278446T3 (de)
HK (1) HK1034460A1 (de)
NZ (1) NZ508771A (de)
PT (2) PT1741443E (de)
WO (1) WO1999061053A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998012332A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
EP1179072A2 (de) 1999-05-19 2002-02-13 Chiron S.P.A. Neisseria kombinationszusammensetzung
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
BRPI0107679B8 (pt) * 2000-01-17 2021-05-25 Chiron Spa composição compreendendo vesículas de membrana externa do grupo sérico b de neisseria meningitidis e um componente inorgânico e uso da mesma
KR20030024811A (ko) 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
BR0211494A (pt) 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
DE602004032481D1 (de) * 2003-10-02 2011-06-09 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen Meningitis
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP1855715B1 (de) 2005-01-27 2013-03-13 Children's Hospital & Research Center at Oakland Gna1870-basierte vesikelimpfstoffe für breitbandschutz gegen neisseria meningitidis-bedingte erkrankungen
PT2200642E (pt) 2007-10-19 2012-05-30 Novartis Ag Formulações de vacinas meningocócicas
CN102596240B (zh) * 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
JP5976652B2 (ja) 2010-09-10 2016-08-24 ワイス・エルエルシー 髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CN104334187B (zh) 2012-03-09 2017-04-05 辉瑞公司 脑膜炎双球菌组合物及其方法
US9526776B2 (en) 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
CA2882382A1 (en) 2012-09-18 2014-03-27 Novartis Ag Outer membrane vesicles
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
WO2015033251A2 (en) 2013-09-08 2015-03-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
KR102567845B1 (ko) 2017-01-31 2023-08-17 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
AU640118B2 (en) 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
ES2145072T3 (es) 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
EP0710118B1 (de) 1994-04-20 1998-11-25 U.S. Department Of The Army Impfstoff gegen gram-negative bakterielle infektionen
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
PT854729E (pt) * 1995-09-18 2004-08-31 Us Army Med Res Mat Com Usamrm Metodos melhorados para a producao de vacinas de subunidade multivalentes de proteossomas complexados nao covalentemente
DE19601754A1 (de) * 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) * 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
WO1998008543A1 (en) * 1996-08-27 1998-03-05 Chiron Corporation Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
EP0994723A1 (de) * 1997-06-24 2000-04-26 Chiron Corporation Verfahren um erwachsenen mit anti-meningokokken impfstoffzusammensetzungen zu immunizieren
CN1272062A (zh) * 1997-07-17 2000-11-01 北美疫苗公司 含有b组脑膜炎球菌膜孔蛋白和流感嗜血菌多糖的免疫偶联物
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
ES2278446T3 (es) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. Vacunas combinadas b/c contra la meningitis.
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
KR20030024811A (ko) 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CN102302776B (zh) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
DE602004032481D1 (de) 2003-10-02 2011-06-09 Novartis Vaccines & Diagnostic Kombinationsimpfstoffe gegen Meningitis

Also Published As

Publication number Publication date
EP1079857B1 (de) 2006-11-29
WO1999061053A1 (en) 1999-12-02
JP2009292851A (ja) 2009-12-17
DE69934225D1 (de) 2007-01-11
ES2485940T3 (es) 2014-08-14
US8007815B1 (en) 2011-08-30
DE69934225T2 (de) 2007-09-27
EP1079857A1 (de) 2001-03-07
NZ508771A (en) 2003-08-29
ES2278446T3 (es) 2007-08-01
AU761495B2 (en) 2003-06-05
PT1079857E (pt) 2007-02-28
PT1741443E (pt) 2014-07-31
EP2796148A2 (de) 2014-10-29
AU4221599A (en) 1999-12-13
HK1034460A1 (en) 2001-10-26
AU2003244518A1 (en) 2003-09-25
ATE346609T1 (de) 2006-12-15
JP5074644B2 (ja) 2012-11-14
JP2002516292A (ja) 2002-06-04
BR9910749A (pt) 2001-02-13
DK1079857T3 (da) 2007-01-29
CA2332963A1 (en) 1999-12-02
CY1107550T1 (el) 2013-03-13
EP2796148A3 (de) 2015-02-25

Similar Documents

Publication Publication Date Title
CA2332963C (en) Combination meningitidis b/c vaccines
AU2010200336B2 (en) Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen
CA2090673A1 (en) Vaccine compositions
EP1005367A2 (de) Bordetella pertussis antigens als träger in impfstoff-konjugaten
EP1741443B1 (de) Kombinierte Meningitis B/C Impfstoffe
AU2013206190A1 (en) Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen
AU2003213540B2 (en) Combination meningitidis B/C vaccines
MXPA00011664A (en) Combination meningitidis b/c vaccines
AU2006202664B2 (en) Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190528